Skip to main content

UM School of Medicine’s Institute of Human Virology Awarded Grants to Strengthen COVID-19 Response in Sub-Saharan Africa

June 02, 2020 | John Nagiecki

Man CharuratThe Center for International Health, Education and Biosecurity (Ciheb) at the University of Maryland School of Medicine’s Institute of Human Virology was awarded $4 million from the U.S. Centers for Disease Control and Prevention (CDC) to support coronavirus disease 2019 (COVID-19) response activities in Botswana, Nigeria, Malawi, and Mozambique.

"Low-resource regions in Africa are vulnerable to the impact of COVID-19, and Ciheb is engaged and well-positioned to build upon our partnerships with ministries of health in each country to further the understanding of the pandemic, while strengthening their capacity to monitor and control the spread of the disease,” said Man E. Charurat, PhD, MHS, professor of medicine, Ciheb global director and director, Division of Epidemiology and Prevention, Institute of Human Virology, University of Maryland School of Medicine.

Kristen StaffordIn Nigeria, the award of $2.1 million will support a population-based epidemiological study to estimate COVID-19 prevalence in communities, household transmission, the proportion of subclinical infections, and risk factors for infection, using methods similar to the WHO Unity Studies to ensure comparability across countries.

The study will be led by principal investigator, Kristen Stafford, PhD, MPH, assistant professor of epidemiology and public health and Ciheb Associate Director, Institute of Human Virology, University of Maryland School of Medicine. Data generated from this study will characterize the spectrum of disease resulting from COVID-19 and provide critical information on the clinical course and outcomes of COVID-19. 

This information will be vital to inform local response efforts, including the development of strategies to target potential prevention and control interventions to high risk groups, develop clinical treatment guidelines to mitigate the effects of COVID-19, and strengthen the health system to respond to the pandemic.  In addition, technical assistance will be provided to enhance and strengthen disease surveillance and improve laboratory diagnostics.

 Ndwapi, NdwapiIn Botswana, under the leadership of country director Ndwapi, Ndwapi, MD, the award of $810,000 will support the development of an influenza-like illness (ILI) and severe acute respiratory infection (SARI) surveillance systems for the Botswana Ministry of Health and Wellness to capture community circulation and transmission of SARS-CoV-2. This will include establishing sentinel surveillance sites to more rapidly detect SARS-CoV-2.

Other measures that will be supported include the development of a web-based surveillance data entry platform to enable real-time situational awareness, the implementation of a standardized approach to data collection and reporting for comparability across sites in Botswana and facilitating timely sharing of surveillance data between human and animal sectors to inform evidence-based planning. The funding will also support measures to facilitate social distancing and decongestion at healthcare facilities by constructing temporary consultation areas and the procurement of personal protective equipment for healthcare workers.

In Malawi, the award of $795,000 will enhance the Malawi Ministry of Health’s laboratory capacity in five primary areas: training, quality control, supplies, services, and waste management. This initiative is led by Alash’le Abimiku, PhD, professor of medicine, Institute of Human Virology, University of Maryland School of Medicine and the executive director of the International Research Center of Excellence at the Institute of Human Virology–Nigeria.

Interventions will include bench-level technical assistance and training at 10 molecular labs located across the nation to ensure technicians are skilled in implementing diagnostics for COVID-19, using both the Daan Gene Assay and the CDC COVID-19 protocol. Laboratory quality assurance will also be improved with a focus on specimen collection management and tracking, data collection and management, proficiency testing, and external quality assurance.

Alash'le AbimikuIn Mozambique, the award of $380,000 will ensure maintenance for ABI 7500 and ABI 7900 PCR instruments installed at the National Institute of Health in Maputo Province. These instruments are used for COVID-19 diagnosis and regular maintenance is necessary to ensure accurate diagnoses.

The award, also led by Alash’le Abimiku, PhD, will also provide GeneXpert operations training, support the installation of the COVID-19 software and instrument hardware, and ensure DISA-Lab operational connectivity on GeneXpert instruments at 11 locations across the nation. The award will also fund the procurement of SARS- CoV-2 diagnostic test-kits.

Additionally, Ciheb is leading cross-cutting COVID-19 response efforts in each of the eight countries in which it works. Ciheb teams are developing clinical guidelines, improving patient triage, developing and implementing clinic safety protocols, and procuring needed personal protective equipment.

“The global threat of this pandemic requires that we work cooperatively with other nations on developing and implementing targeted response actions,” said Dean E. Albert Reece, MD, PhD, MBA, who is also Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. and Akiko K. Bowers Distinguished Professor, University of Maryland School of Medicine.  “The School of Medicine, through Ciheb and the Institute of Human Virology, is proud to contribute its expertise to the ongoing work on the African continent supported by the U.S. Centers for Disease Control and Prevention.”

About Ciheb

Ciheb is a leading international education, development and research center within the University of Maryland School of Medicine. Ciheb was founded in 2016 by the Institute of Human Virology at the University of Maryland School of Medicine. Ciheb’s mission is to conduct research, provide training, and implement evidence-based interventions at the patient, community, and population levels for sustainable positive impact. Ciheb’s global teams work to expand health service capacity and quality of service in developing nations confronting epidemic diseases such as HIV/AIDS, tuberculosis, and malaria, and also develop strategies for early detection and rapid response to biological threats as part of the U.S. Global Health Security Agenda. For more information, see Ciheb.org.

About the Institute of Human Virology

Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland and the University of Maryland Medical System, IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in all of virology. The IHV combines the disciplines of basic research, epidemiology and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders - most notably, HIV the virus that causes AIDS. For more information, see www.ihv.org.

Contact

John Nagiecki
JNagiecki@ihv.umaryland.edu
410.706.5468

Related stories

    Wednesday, September 08, 2021

    UM School of Medicine Reaching Underserved Communities Through Grass Roots Efforts to Increase COVID-19 Vaccination Rates

    In an effort to increase COVID-19 vaccination rates among children and families, and ultimately help bring the pandemic under control, the Department of Family & Community Medicine (DFCM) and the Department of Psychiatry at the University of Maryland School of Medicine (UMSOM) are partnering with key community and faith-based groups in Baltimore city to reach the most vulnerable and underserved communities. This partnership will also extend across Maryland, Delaware, Virginia, and West Virginia.


    Wednesday, July 07, 2021

    UM School of Medicine Researchers Develop Two Rapid Tests for COVID-19 Using Innovative Techniques

    Researchers at the University of Maryland School of Medicine (UMSOM) have developed two rapid diagnostic tests for COVID-19 that are nearly as accurate as the gold-standard test currently used in laboratories. Unlike the gold-standard test, which extracts RNA and uses it to amplify the DNA of the virus, these new tests can detect the presence of the virus in as little as five minutes using different methods.


    Wednesday, June 09, 2021

    Global Study of Microbes in 60 Cities Finds Each Has Unique Fingerprint of Viruses and Bacteria

    Each city has its own unique microbiome, a “fingerprint” of viruses and bacteria that serves as type of city profile, according to a new study from an international consortium of researchers that included a team from the University of Maryland School of Medicine (UMSOM). The international project, which sequenced and analyzed samples collected from public transit systems and hospitals in 60 cities around the world, was published today in the journal Cell.


    Monday, March 29, 2021

    Cancer Drug Lessens the Toxicity of a Protein from the Virus that Causes Covid-19, UM School of Medicine Study Finds

    University of Maryland School of Medicine (UMSOM) researchers have identified the most toxic proteins made by SARS-COV-2—the virus that causes COVID-19 – and then used an FDA-approved cancer drug to blunt the viral protein’s detrimental effects. In their experiments in fruit flies and human cell lines, the team discovered the cell process that the virus hijacks, illuminating new potential candidate drugs that could be tested for treating severe COVID-19 disease patients. Their findings were published in two studies simultaneously on March 25 in Cell & Bioscience, a Springer Nature journal.


    Tuesday, March 16, 2021

    New Study Finds Healthcare Settings Do Not Pose Added Risk Factor for Covid-19 Infection Spread Among U.S. Healthcare Personnel

    Healthcare personnel who were infected with COVID-19 faced stronger risk factors outside of the workplace than in their hospital or healthcare settings. That is the finding of a new study published today in the Journal of the American Medical association's JAMA Network Open conducted by University of Maryland School of Medicine (UMSOM) researchers and colleagues at the Centers for Disease Control and Prevention (CDC) and three other universities.


    Thursday, January 21, 2021

    UM School of Medicine Hosted Media Availability for Ensuring Trust in COVID-19 Vaccine Event

    On January 22, 2021 at 2 p.m., the University of Maryland School of Medicine (UMSOM) hosted Black faith-based leaders, COVID-19 research volunteers, and “America’s Doctor,” Anthony Fauci, MD. The event provided straight talk about fears, trust issues, and why we need our Black and Brown community to be a part of COVID-19 vaccine research.


    Tuesday, January 05, 2021

    Dr. Kathleen Neuzil, World-renowned Leader in Vaccine Research, Receives Moderna Vaccine

    Kathleen Neuzil, MD, MPH, FIDSA, the Myron M. Levine, MD, DTPH, Professor of Vaccinology and Director of the University of Maryland School of Medicine’s (UMSOM)’s Center for Vaccine Development and Global Health (CVD), received her first injection of the Moderna vaccine for COVID-19 on December 31. Researchers at the University of Maryland School of Medicine (UMSOM) played an integral part in the dedicated work that led to the U.S. Food and Drug Administration issuing an Emergency Use Authorization for the Moderna vaccine in December.


    Tuesday, January 05, 2021

    University of Maryland School of Medicine Begins Phase 3 Trial of Novavax COVID-19 Vaccine Candidate

    Researchers at the University of Maryland School of Medicine (UMSOM) will participate in a Phase 3 clinical trial of an investigational COVID-19 vaccine to protect against SARS-CoV-2, the coronavirus causing COVID-19 that continues to impact millions of people around the world. The clinical trial will test the safety and effectiveness of NVX-CoV2373, being developed by U.S. biotechnology company, Novavax, Inc., based in Gaithersburg, MD.


    Tuesday, December 22, 2020

    Largest Study of Its Kind Identifies Which COVID-19 Patients Face the Greatest Risk of Mortality During Hospitalization

    Hospitalized COVID-19 patients have a greater risk of dying if they are men or if they are obese or have complications from diabetes or hypertension, according to a new study conducted by University of Maryland School of Medicine (UMSOM) researchers. In a study published in the journal Clinical Infectious Diseases, the researchers evaluated nearly 67,000 hospitalized COVID-19 patients in 613 hospitals across the country to determine the link between certain common patient characteristics and the risk of dying from COVID-19. Their analysis found that men had a 30 percent higher risk of dying compared to women of the same age and health status. Hospitalized patients who were obese, had hypertension or poorly managed diabetes had a higher risk of dying compared to those who did not have these conditions. Those aged 20 to 39 with these conditions had the biggest difference in their risk of dying compared to their healthier peers.


    Thursday, November 19, 2020

    Promising Results Seen in Pfizer/BioNTech COVID-19 Vaccine After Phase 1 Trial by University of Maryland School of Medicine

    Just six months after beginning a clinical development program that first enrolled here at the University of Maryland School of Medicine (UMSOM), Pfizer and BioNTech report interim results showing an mRNA COVID-19 vaccine had no serious safety concerns and has been found to be 95 percent effective in protecting individuals from COVID-19.


    Friday, November 13, 2020

    UM School of Medicine and School of Pharmacy Researchers Identify Promising New Compounds to Potentially Treat Novel Coronaviruses

    Researchers at the University of Maryland School of Medicine (UMSOM) and School of Pharmacy (UMSOP) have discovered new drug compounds to potentially treat the novel coronavirus that causes COVID-19. The compounds disrupt the functioning of a protein complex inside human cells that the researchers discovered is critical for the replication and survival of coronaviruses. This finding could lead to the development of new broad-spectrum antiviral drugs that target viruses such as influenza, Ebola and coronaviruses, according to a new study published today in the Proceedings of the National Academy of Sciences (PNAS) journal.


    Thursday, October 22, 2020

    New Landmark Study at UM School of Medicine Finds Aspirin Use Reduces Risk of Death in Hospitalized COVID-19 Patients

    Hospitalized COVID-19 patients who were taking a daily low-dose aspirin to protect against cardiovascular disease had a significantly lower risk of complications and death compared to those who were not taking aspirin, according to a new study led by researchers at the University of Maryland School of Medicine (UMSOM). Aspirin takers were less likely to be placed in the intensive care unit (ICU) or hooked up to a mechanical ventilator, and they were more likely to survive the infection compared to hospitalized patients who were not taking aspirin, The study, published today in the journal Anesthesia and Analgesia, provides “cautious optimism,” the researchers say, for an inexpensive, accessible medication with a well-known safety profile that could help prevent severe complications.


    Tuesday, June 16, 2020

    UM School of Medicine Researchers Receive Federal Funding to Rapidly Test New Treatments for COVID-19

    Researchers at the University of Maryland School of Medicine (UMSOM) will be partnering on an agreement funded by the federal government’s Defense Advanced Research Projects Agency (DARPA) to rapidly test hundreds of drugs, approved and marketed for other conditions, to see whether any can be repurposed to prevent or treat COVID-19. The compounds will be tested in studies using state-of-the-art technologies in the laboratory of coronavirus researcher Matthew Frieman, PhD., Associate Professor of Microbiology and Immunology at the University of Maryland School of Medicine. UMSOM will receive up to $3.6 million over the next year to fund this effort.


    Monday, June 15, 2020

    UM School of Medicine Researchers Help Identify Potent Antibody Cocktail with Potential to Treat COVID-19

    Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19. Their research, conducted in collaboration with scientists at Regeneron Pharmaceuticals, was published today in the journal Science. The study demonstrates the rapid process of isolating, testing and mass-producing antibody therapies against any infectious disease by using both genetically engineered mice and plasma from recovered COVID-19 patients.


    Monday, June 01, 2020

    In A COVID-19 World, Another Threat to the Health of Our Children

    In the U.S., our children rarely fall ill to grave infections because they are protected by vaccines. Serious illnesses like measles, mumps, congenital rubella syndrome, chickenpox, diphtheria, tetanus, whooping cough, rotavirus diarrhea, hepatitis (A and B), polio and bacterial meningitis are all preventable through routine childhood vaccinations.


    Thursday, May 28, 2020

    UM School of Medicine Researchers Develop Experimental Rapid COVID-19 Test Using Innovative Nanoparticle Technique

    Scientists from the University of Maryland School of Medicine (UMSOM) developed an experimental diagnostic test for COVID-19 that can visually detect the presence of the virus in 10 minutes. It uses a simple assay containing plasmonic gold nanoparticles to detect a color change when the virus is present. The test does not require the use of any advanced laboratory techniques, such as those commonly used to amplify DNA, for analysis. The authors published their work last week in the American Chemical Society’s nanotechnology journal ACS Nano.


    Thursday, May 21, 2020

    UM School of Medicine Begins First Innovative Trial of Experimental Stem Cell Therapy to Reduce Deaths in Sickest COVID-19 Patients

    Researchers at the University of Maryland School of Medicine (UMSOM) have begun testing an experimental stem cell therapy developed by Mesoblast Limited to treat hospitalized COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS) who are on ventilators to help them breathe. The trial, which is being conducted at the University of Maryland Medical Center (UMMC) and additional sites across the U.S, will involve a total of 300 patients randomized to receive either the drug remestemcel-L or a placebo in addition to the recommended standard of care to manage severe COVID-19 infections. The first patient in this national trial was treated at UMMC.


    Tuesday, May 05, 2020

    UM School of Medicine is First in U.S. to Test Unique RNA Vaccine Candidate for COVID-19

    In a significant development in the global effort to discover a safe and effective vaccine for COVID-19, researchers at the University of Maryland School of Medicine (UMSOM) became the first in the U.S. to begin testing experimental COVID-19 vaccine candidates developed by Pfizer and BioNTech. The research, funded by Pfizer Inc., will study the safety, efficacy, and dosing of an experimental mRNA -based vaccine.


    Thursday, April 23, 2020

    UM School of Medicine Researchers Test Remdesivir as Potential Therapy for COVID-19 Patients

    Researchers at the University of Maryland School of Medicine (UMSOM) are testing the effectiveness of the investigational antiviral drug remdesivir in hospitalized adult patients with SARS-CoV-2 (COVID-19). The randomized controlled clinical trial is evaluating the safety and effectiveness of the drug, and it is part of a national study funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).


    Friday, April 10, 2020

    University of Maryland School of Medicine Launches New Large Scale COVID-19 Testing Initiative

    University of Maryland School of Medicine (UMSOM) Dean E. Albert Reece, MD, PhD, MBA, announced today the launch of a large-scale COVID-19 Testing Initiative that will significantly expand testing capability over the coming weeks, enabled by new funding of $2.5 million from the State of Maryland.


    Wednesday, April 01, 2020

    Important Coronavirus Update from Dean Reece 04-01

    I am sure you are aware of Governor Hogan’s Executive Order that requires all residents of Maryland to stay at home, except for essential activities. The Governor continues to emphasize that we are still just at the beginning of this crisis in Maryland. While the State has been taking the lead with early containment efforts, we are now at a critical point. Each of our actions can lessen the expected surge in cases over the next few weeks.


    Wednesday, March 25, 2020

    Kids & COVID-19 Website Provides Resources for Pediatric Healthcare Providers and Families

    The University of Maryland School of Medicine has launched a special COVID-19 website for pediatric healthcare providers and practices, parents, and children. This resource brings together important research, professional guidance for pediatric practices, and practical tips for parents and caregivers.


    Wednesday, March 25, 2020

    Important Coronavirus Update from Dean Reece

    As we continue to move forward in these challenging times, I would like to bring you a message of encouragement and hope. First and foremost, please be assured and confident that we are, and will continue to do, everything we can to ensure the health and well-being of all within our community. As you will see in this briefing, significant steps are being taken by the State of Maryland, the University of Maryland Medical System and the University of Maryland, Baltimore to ensure that everyone is healthy and safe. We must each do whatever is necessary to ensure that our health comes first.


    Tuesday, February 25, 2020

    Washington Post Visits UM School of Medicine Laboratories, Meets with Scientists About Coronavirus

    Result is front-page feature coverage of UMSOM’s leading work in studying the Virus


    Wednesday, January 29, 2020

    University of Maryland School of Medicine Mobilizes Virus Experts to prepare for Potential Coronavirus Outbreak

    As public health officials around the world are monitoring a new coronavirus strain (2019-nCoV) first identified in the Wuhan City, Hubei Province, China, the University of Maryland School of Medicine (UMSOM) is mobilizing its physicians and scientists in the UMSOM’s Center for Vaccine Development and Global Health (CVD), and in its Department of Microbiology & Immunology, to study the virus and test potential vaccines and other therapies. In addition, the UMSOM is collaborating with the University of Maryland Medical Center (UMMC) on rapid response and preparedness planning in the event of a growing outbreak.


    Tuesday, November 22, 2016

    IHV Awarded $138M to combat HIV/AIDS in Africa & Launches Center for International Health, Education, & Biosecurity

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine announced today more than $138 million in multiple five-year grants awarded by the Centers for Disease Control and Prevention to combat HIV/AIDS in Kenya, Tanzania, Zambia, and Nigeria. The Institute concurrently announced the formation of the IHV Center for International Health, Education, & Biosecurity (CIHEB), and its newly appointed director, Deus Bazira Mubangizi, DrPH, MBA, MPH, Assistant Professor of Medicine, Director, Center for Health, Education, & Biosecurity, Institute of Human Virology, University of Maryland School of Medicine.


    Friday, April 14, 2000

    Letter from Dean Reece to FPI Patients

    The COVID-19 pandemic has changed many aspects of our lives, from the way we shop and eat to how we connect with family and friends. While the virus itself has had strong and sometimes devastating effects on our community, the fear of its potential impact continues to influence responses and even cripple thoughts and actions.